Endogenous bornavirus-like nucleoprotein 2 (EBLN2)

Endogenous bornavirus-like nucleoprotein 2 (EBLN2) is a protein-coding gene located on chromosome 3p13 in humans[3][4][5]. It is derived from the integration of ancient bornavirus nucleoprotein mRNA into the primate genome via a LINE-1 mediated event, at least 40 million years ago[1][2]. While it is homologous in sequence to the bornavirus nucleoprotein (N), EBLN2 has acquired novel host functions. EBLN2 localizes to mitochondria and can inhibit apoptosis, likely contributing to cell viability and survival[2]. There is no evidence that it serves as a therapeutic drug target, and no drugs are known to interact with it. EBLN2 can interact with human cellular proteins and may have had roles in host-virus interactions or viral resistance during evolution, but it is not a receptor, enzyme, transporter, or traditional disease-associated modality[1][2][6]. Its clinical and therapeutic relevance remains largely unexplored, and it is often considered in evolutionary, genomic, or molecular biology contexts. EBLN2 is not a standard therapeutic target (such as a receptor, enzyme, etc.), nor is it associated with any known drug interventions or diagnostic biomarkers[6]. There are no reported safety or toxicology concerns related to EBLN2, as it is an endogenous, likely non-pathogenic protein[6]. Some confusion exists due to overlap with EBLN1/EBLN2 naming and the evolutionary/viral origin of the sequence, so careful attention is needed to context and usage[1][2].

Other names

Endogenous Bornavirus like nucleoprotein 2EBLN2Endogenous Borna-like N element-2EBLN-2endogenous Borna-like N element 2GK006